LGM
AMLX icon

Logos Global Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Logos Global Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29M Sell
350,000
-350,000
-50% -$5.41M 0.27% 54
2026
Q1 		$9.73M Sell
700,000
-250,000
-26% -$3.52M 0.49% 48
2025
Q4 		$11.5M Sell
950,000
-500,000
-34% -$6.79M 0.69% 41
2025
Q3 		$19.7M Buy
+1,450,000
New +$13.6M 1.77% 26

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Logos Global Management's AMLX Position: Q2 2026 in Review

Logos Global Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 50% in Q2 2026, selling an estimated $5.41M and leaving 350,000 shares worth $6.29M. The position accounts for 0.27% of the portfolio, ranked #54.

Logos Global Management first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. The position peaked at $19.7M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Logos Global Management held 350,000 shares of Amylyx Pharmaceuticals worth $6.29M as of Q2 2026.
  • Logos Global Management sold 350,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $5.41M.
  • Amylyx Pharmaceuticals made up 0.27% of Logos Global Management's portfolio in Q2 2026, its #54 holding.
  • Logos Global Management first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Logos Global Management's Amylyx Pharmaceuticals position peaked at $19.7M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.